Compare NIC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NIC | GPCR |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.8B |
| IPO Year | 2002 | 2023 |
| Metric | NIC | GPCR |
|---|---|---|
| Price | $164.36 | $16.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | ★ $195.20 | $104.86 |
| AVG Volume (30 Days) | 111.9K | ★ 829.6K |
| Earning Date | 10-20-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ 21.49 | N/A |
| EPS | ★ 6.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $75.22 | N/A |
| Revenue Next Year | $8.76 | N/A |
| P/E Ratio | $25.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $119.31 | $16.88 |
| 52 Week High | $180.00 | $94.90 |
| Indicator | NIC | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.43 | 22.78 |
| Support Level | $165.26 | N/A |
| Resistance Level | $171.98 | $22.54 |
| Average True Range (ATR) | 3.79 | 1.42 |
| MACD | -1.12 | 0.03 |
| Stochastic Oscillator | 7.76 | 1.14 |
Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.